Navigation Links
Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
Date:3/26/2009

EMERYVILLE, Calif., March 26 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced today that it has hired RBC Capital Markets as its exclusive financial advisor to assist in the evaluation of various options to enhance shareholder value, including a potential sale of the Company or its major assets.

"We have retained RBC Capital Markets to assist us in efficiently determining if there is a transaction more beneficial to our shareholders than a liquidation," stated William Fletcher, acting Chief Executive Officer. "We have a duty to our shareholders to maximize the value of NTI. We intend to proceed expeditiously in this process while continuing to wind-down operations, cut expenses and preserve cash. If our evaluation of strategic options does not result in a transaction that meets our objectives, NTI will act expeditiously to return as much cash as possible to our shareholders through a liquidation or other means."

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions and other serious unmet medical needs. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials as a potential new drug to treat acute ischemic stroke. NTI has recently chosen not to extend its early-stage research program for Alzheimer's disease beyond the first year of a collaborative agreement with the Buck Institute. NTI has rights to receive payments from an approved drug for Alzheimer's disease and an investigational drug which has recently completed a Phase 3 trial for brain swelling.

NOTE: Except for the historical information contain
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
2. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
3. Neurobiological Technologies Announces Suspension of Viprinex Development
4. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
5. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
6. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
7. Neurobiological Technologies Sets Date for First Quarter Financial Results
8. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
9. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
10. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
(Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 a2z Inc. ... ChirpE Mobile App, AACC Pathfinder, in its 2014 ... AACC’s annual meeting is planned for July 29-31, 2014 ... place to be to connect with global leaders in ... management, and other areas of breaking science in laboratory ...
(Date:7/22/2014)... July 22, 2014 The Board of Directors of ... has declared a quarterly dividend of 54.5 cents per common ... on September 9, 2014. The indicated annual dividend rate is ... BD is a leading medical technology company that partners with ... pressing and evolving health needs. Our innovative solutions are focused ...
Breaking Biology Technology:BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... NEW HAVEN, Conn., Sept. 9 Rib-X ... company focused on the,discovery and development of ... announced today the formation of its,Clinical Advisory ... disease,specialists, will provide oversight and counsel on ...
... Expert Physician Commentaries ... and Practice Developments, Expert Physician Panel Selects ... Treatment as Year,s Most Influential Oncology Development, ... (http://www.OncologySTAT.com ),a free web site featuring high-quality, scientifically ...
... Clinical Programs, With Three Bavituximab Phase ... -, - Updated Initial Data from Bavituximab Plus Docetaxel Phase II Breast, Cancer Trial ... ... Defense Threat Reduction Agency ...
Cached Biology Technology:Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 2Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 3OncologySTAT Advisors Name Year's Top Developments in Cancer Treatment and Research 2OncologySTAT Advisors Name Year's Top Developments in Cancer Treatment and Research 3OncologySTAT Advisors Name Year's Top Developments in Cancer Treatment and Research 4Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 2Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 3Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 4Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 5Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 6Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 7Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 8Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 9Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 10
(Date:7/23/2014)... TORONTO, July 23, 2014 Migratory songbirds are disappearing, ... as climate change, loss of habitat, acid rain and ... remained missing: where do these birds go once they ... be encountering along the way? , To answer this ... have created the first ever migratory connectivity map produced ...
(Date:7/23/2014)... fly Chrysomya megacephala is commonly found in ... determine the time of death, referred to as the ... of C. megacephala from Tamil Nadu is ... and molecular characterization through generation of DNA barcoding. This ... open access Biodiversity Data Journal . , ...
(Date:7/23/2014)... potential for clinical use of induced pluripotent stem ... previously been hindered by the risk of dysregulated ... ability to use etoposide treatment to halt teratoma ... disease, specifically acute myocardial infarction, is demonstrated in ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Biology News(10 mins):York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2Dead body feeding larvae useful in forensic investigations 2
... LAS VEGAS , Jan. 6, 2014  LG Electronics (LG) ... Heart Rate Earphones, two wearable products that mark the company,s ... Consumer Electronics Show (CES) in Las Vegas ... devices so that monitoring one,s health requires no additional effort ...
... the food industry at sublethal doses may be endangering, ... in bacteria and enhancing their ability to form harmful ... in Applied and Environmental Microbiology . This is ... The study was designed to test whether exposing ...
... in small proteins that help convey electrical signals throughout the ... to results of a new Johns Hopkins study study published ... in December using spider, scorpion and sea anemone venom. ... sodium channels that are vital to our well-beingthey trigger action ...
Cached Biology News:LG Jumps Into Fitness Tech At CES With Lifeband Touch And Heart Rate Earphones 2LG Jumps Into Fitness Tech At CES With Lifeband Touch And Heart Rate Earphones 3Improper use of biocides in food production may endanger public health 2Tiny proteins have outsized influence on nerve health 2Tiny proteins have outsized influence on nerve health 3
... a platform for fully automated systems for ... easily be configured for applications ranging from ... allows closed loop screening, which means it ... generating, cherry picking and follow up studies ...
... devices for the fast and reliable clarification/filtration of ... 500 l. They can be used in fixed ... Features: High-flux Polyethersulphonemembrane 0.8 ... volume ( Fast and reproducible performance ...
... Prelude Workstation fully automates pharmaceutical sample ... extraction, sample transfer, mixing and dilutions. ... UV detection. The Prelude performs these ... CFR Part 11. The Prelude ...
... in any standard fixed-angle microcentrifuge rotor ... g.,Spin- centrifuge tube filters consist of ... centrifuge tube. They filter by centrifugation ... sample preparation, removal of cells from ...
Biology Products: